Bearishness Around Pfizer Gilead Sparks Opportunity
Wall Street traders weigh a contrarian opportunity as Pfizer and Gilead trade below fair value amid rising bearish se...
Offer practical starter options for 2024, including how to evaluate coins, wallets, and purchasing steps for beginners.
23,507 articlesWall Street traders weigh a contrarian opportunity as Pfizer and Gilead trade below fair value amid rising bearish se...
IBM's latest profit warning sheds light on the strength and limits of AI demand, cloud growth, and enterprise spendin...
Five cities are in a high-stakes chase to land a blockbuster deal tied to LeBron James, hoping for lasting local grow...
Investors are watching a policy rethink unfold. This article explains how chair kevin warsh just signals a new inflat...
A niche bond ETF focused on mid-tier CLO tranches is drawing buyers as rate expectations stay elevated. The fund aims...
As 2027 nears, the latest social security cola forecasts hint at a bigger raise. But higher checks aren’t a guarantee...
An external review shows the Gates Foundation met with Jeffrey Epstein roughly 30 times between 2011 and 2014, despit...
Archer Aviation takes a bold leap with Halo, a pilotless, hybrid-electric tilt-rotor aircraft developed with Anduril....
In July’s session, AT&T surprised with subscriber growth that outweighed a revenue miss, lifting its stock and offeri...
Chemed has faced a challenging year, even as its business lines stay essential. This article breaks down the drivers ...
January 2026 brings a shift in power toward buyers. Homes stay on the market longer, and sellers are more willing to ...
Xenon stock sits at $42 as insiders trim significant positions ahead of a pivotal March Phase 3 readout. This guide b...